Engineering Safer Psychedelics for Treating Addiction.
Neuroscience Insights 2021 DOI: 10.1177/26331055211033847 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Addiction Ibogaine Neuroplasticity |
| Keywords | Psychedelic Tbg Neuropsychiatric disorder Psychoplastogen Tabernanthalog |
| Citations | 38 |
| Key findings | Non-hallucinogenic psychoplastogens like tabernanthalog show long-lasting therapeutic effects in preclinical models of alcohol and opioid addiction, indicating hallucinations may not be required for psychedelic-based addiction treatments. |
Abstract
Addiction is best described as a disorder of maladaptive neuroplasticity involving the simultaneous strengthening of reward circuitry that drives compulsive drug seeking and weakening of circuits involved in executive control over harmful behaviors. Psychedelics have shown great promise for treating addiction, with many people attributing their therapeutic effects to insights gained while under the influence of the drug. However, psychedelics are also potent psychoplastogens-molecules capable of rapidly re-wiring the adult brain. The advent of non-hallucinogenic psychoplastogens with anti-addictive properties raises the intriguing possibility that hallucinations might not be necessary for all therapeutic effects of psychedelic-based medicines, so long as the underlying pathological neural circuitry can be remedied. One of these non-hallucinogenic psychoplastogens, tabernanthalog (TBG), appears to have long-lasting therapeutic effects in preclinical models relevant to alcohol and opioid addiction. Here, we discuss the implications of these results for the development of addiction treatments, as well as the next steps for advancing TBG and related non-hallucinogenic psychoplastogens as addiction therapeutics.
Comparable studies
Other narrative reviews on ibogaine for addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation Humans, animals | 2015 | Review | |
| Ibogaine in the treatment of substance dependence. | 2013 | Review | |
| Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. | 2008 | Review | |
| A review of chemical agents in the pharmacotherapy of addiction. | 2002 | Review | |
| IUPHAR - invited review - Ibogaine - A legacy within the current renaissance of psychedelic therapy. | 2023 | Review |
Citations in the library
Cited by 28
- Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity. Biochemistry January 21, 2022
- Psychedelic therapy in the treatment of addiction: the past, present and future Frontiers in Psychiatry June 12, 2023
- Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy CNS Spectrums July 11, 2022
- Psychedelic-inspired approaches for treating neurodegenerative disorders. Journal of Neurochemistry July 1, 2022
- Mini-review: The neurobiology of treating substance use disorders with classical psychedelics Frontiers in Neuroscience April 17, 2023
and 23 more in the library
Cites 14
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. ACS Pharmacology & Translational Science December 10, 2020
- A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 2021
- The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects ACS Pharmacology & Translational Science December 10, 2020
- Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years Therapeutic Advances in Psychopharmacology March 18, 2016
and 9 more in the library